Augme Technologies Looks to Finish Its Dismal June with Another Dismal Day, Down 13% (AUGT)

To look at Augme’s year-to-date trading record is to envision a young Ansel Adams’ first views of Yosemite. The craggy, peak and valley filled chart, that is Augme’s YTD volatility, is to glance at the majesty of a mountain range captured by a Horatio-Alge-filled westward bound mind. Augme (OTC:AUGT) may not merit attention if not for its resilience and upside, nearly each time it approaches a new low.

As the Twitterverse erupted following today’s landmark Supreme Court decision, Augme tracked it. Whether it can properly monetize its proprietary AD LIFE® system, which tracks mobile marketing campaigns and mobile use over multiple platforms, remains a mystery.

Augme’s mission statement includes the word healthcare. A word that today brought high volume trading in each and every market for seemingly healthcare tied companies, and Augme was no exception.

The company is the only interactive media tracker that provides a patented end to end mobile advertising platform and is eagerly awaiting the potential awarding of over 80 pending patents to bolster its portfolio. Augme’s client list is nothing short of impressive, and includes such heavy hitters as Nestle, and MillerCoors. It isn’t going anywhere in the market, but its recent downslide IS representative of general investor confusion.

Yesterday saw the announcement of a conference call to discuss (2013) fiscal first quarter earnings, and prompted high-volume trading based on little to nothing more than this vague news.

The week prior saw a press release that included additional nothingness filled distractions like, “We are able to isolate, commercialize, and patent around these concepts and innovations to create IP-protected capabilities with far reaching coverage across numerous key verticals.”

The use of the word “these” fell short, for most insiders remain undecided, confused, and unable to figure out the object of the modifier…these.

It’s rare to comfortably report about something so vague, but there remains something about Augme that merits attention. If for no other reason then its recent trading volume, take note of Augme. Somebody, somewhere, knows something. There is this “Je ne sais quoi” that just won’t go away. You should find it, trade on it and report back. Good Luck.

Please make sure to read and completely understand our disclaimer at https://www.wallstreetpr.com/disclaimer. While reading this article one must assume that we may be compensated for posting this content on our website.

Published by Brendan Byrne

While studying economics, Brendan found himself comfortably falling down the rabbit hole of restaurant work, ultimately opening a consulting business and working as a private wine buyer. On a whim, he moved to China, and in his first week following a triumphant pub quiz victory, he found himself bleeding on the floor based on his arrogance. The same man who put him there offered him a job lecturing for the University of Wales in various sister universities throughout the Middle Kingdom. While primarily lecturing in descriptive and comparative statistics, Brendan simultaneously earned an Msc in Banking and International Finance from the University of Wales-Bangor. He's presently doing something he hates, respecting French people. Well, two, his wife and her mother in the lovely town of Antigua, Guatemala. You may contact Brendan via his email (brendanbyrne@wallstreetpr.com) or his Google+ page (https://plus.google.com/u/0/116608759701551457422).

Recent Stories

SignUp Now For Our Featured Newsletter